

# Workshop on Development of Long-Acting Treatments for Persons with Hepatitis B

Tuesday, March 18th, 2025  
The Westin, Los Angeles, California

## Agenda BEVERLY ROOM

7:00-7:30 AM	<b>Onsite Registration &amp; Breakfast</b>	
7:30-7:35 AM	<b>Welcome</b>	<b>David Thomas,</b> Johns Hopkins University
7:35-8:45 AM	<b>Session 1: Public Health and Medical Imperative for Long-Acting HBV Treatments</b> (10-Minute Presentations including Q&A)	<b>Chair:</b> <b>Norah Terrault</b>
7:35-7:45 AM	<b>Global Public Health Significance</b>	<b>Funmi Lesi,</b> World Health Organization
7:45-7:55 AM	<b>Target Product Profile - Perspective of Persons Living with Hepatitis B</b>	<b>Chari Cohen,</b> Hepatitis B Foundation
7:55-8:05 AM	<b>Target Product Profile - Medical Perspective</b>	<b>Jordan Feld,</b> Toronto General Hospital Research Institute
8:05-8:15 AM	<b>Market Forecast</b>	<b>Paul Domanico</b> Clinton Health Access Initiative
8:15-8:45 AM	<b>Discussion</b>	<b>ALL</b>
8:45-9:55 AM	<b>Session 2: Existing Preclinical Work</b> (10-Minute Presentations including Q&A)	<b>Chair:</b> <b>Andrew Owen</b>
8:45-8:55 AM	<b>ETV Prodrug</b>	<b>Arnab Chatterjee,</b> Calibr-Skaggs at Scripps Research
8:55-9:05 AM	<b>TAF &amp; Other Implants</b>	<b>Marc Baum,</b> Oak Crest Institute of Science
9:05-9:15 AM	<b>Long-Acting Tenofovir Prodrug Formulations</b>	<b>Benson Edagwa</b> University of Nebraska Medical Center

9:15-9:25 AM	<b>TFV-Based Treatments</b>	<b>Rodney Ho,</b> University of Washington
9:25-9:55 AM	<b>Discussion: What Is Needed to Move to the Next Step?</b>	<b>ALL</b>
<b>15-Minute Break</b>		
<b>10:10-11:25 AM</b>	<b>Session 3: Overcoming Roadblocks to Development</b> (10-Minute Presentations including Q&A)	<b>Chair: Veronica Miller</b>
10:10-10:20 AM	<b>Regulatory Considerations for Long-Acting Anti-HBV Formulations</b>	<b>David Thomas,</b> Johns Hopkins University <b>Paul Domanico</b> Clinton Health Access Initiative
10:20-10:30 AM	<b>Low- and Middle-Income Access</b>	<b>Mila Maistat,</b> Medicines Patent Pool
10:30-10:40 AM	<b>Lessons from HIV Drug Development</b>	<b>Charles Flexner,</b> Johns Hopkins University
10:40-11:25 AM	<b>Discussion</b>	<b>ALL</b>
<b>11:25-12:20 PM</b>	<b>Session 4 Industry and Investor Perspective Panel</b>	<b>Chair: Mark Sulkowski</b>
11:25-12:20 PM	<b>The Investment Case for Long-Acting HBV Treatments</b>	<b>Robert Gish,</b> Gish Consulting, LLC <b>Douglas Mayers,</b> DLM Therapeutics, LLC <b>Anuj Gaggar,</b> Assembly Bio <b>Leonard Yaffe,</b> Kessef Capital Management, LLC
<b>Workshop Summary and Adjournment</b>		
12:20-12:25 PM	<b>Next Steps</b>	<b>ALL</b>
12:25-12:30 PM	<b>Final Discussion and Adjournment</b>	<b>David Thomas,</b> Johns Hopkins University
<b>Close of Workshop</b>		

**Workshop Sponsors:**

US NIH R24AI118397 LEAP (<https://www.longactinghiv.org>) and the GHS (<https://global-hepatitis.com>)